Ketamine Therapy in DFW: How It Works for Depression and Anxiety When Nothing Else Has

Magnolia Functional Wellness in Southlake, TX offers physician-supervised IV ketamine infusion therapy for treatment-resistant depression, anxiety, PTSD, and chronic pain. Every infusion is administered under direct physician oversight by Dr. Farhan Abdullah, DO — board-certified internist and attending hospitalist — with individualized dosing, medical monitoring throughout, and integrated follow-up care. Telehealth consultations available statewide for initial evaluation.

I want to start with something I see from the other side of this — as a hospitalist, not as a ketamine provider.

I've admitted the same patients multiple times. The 47-year-old with major depressive disorder who's been on four different antidepressants over eight years, none of which produced sustained remission, admitted again after a crisis. The 38-year-old with PTSD whose anxiety is so refractory that her outpatient psychiatrist has essentially run out of first-line options. The 52-year-old with chronic pain and secondary depression whose quality of life has deteriorated to the point where he stopped leaving the house. These aren't rare cases. They're a pattern I see with regularity in inpatient medicine — the revolving door of psychiatric admissions that happens when treatment-resistant conditions go unaddressed because the tools available in standard care have been exhausted.

Ketamine is not a last resort. But for the patients I'm describing — and for the many more who haven't yet reached inpatient acuity but are living with treatment-resistant depression, anxiety, PTSD, or chronic pain that conventional approaches haven't touched — it's often the most significant clinical intervention available. The evidence for IV ketamine in treatment-resistant depression is among the strongest in the field of interventional psychiatry. Response rates in patients who have failed multiple antidepressants run 50-70% in clinical trials — a number that no standard antidepressant class comes close to matching in that population.

I built Magnolia's ketamine program around what the evidence supports and what the patients I've watched cycle through inpatient units actually needed years before they got there.

What Ketamine Actually Does — and Why It Works When Antidepressants Don't

Standard antidepressants — SSRIs, SNRIs, TCAs, MAOIs — work primarily on monoamine neurotransmitters: serotonin, norepinephrine, dopamine. They take 4-6 weeks to produce meaningful effect, require daily dosing, and in treatment-resistant patients, frequently produce partial response or no response at all. The biological reason for this is increasingly well understood: treatment-resistant depression is often not primarily a serotonin deficiency problem. It's a glutamate signaling and synaptic plasticity problem.

Ketamine is an NMDA receptor antagonist — it works on the glutamate system, not the monoamine system. Within hours of a single IV infusion, ketamine triggers a cascade that includes rapid AMPA receptor activation, BDNF release, and mTOR pathway signaling that promotes synaptogenesis — the formation of new synaptic connections in prefrontal cortical regions that atrophy in chronic depression. This is why ketamine produces antidepressant effects within hours rather than weeks, and why it works in patients whose monoamine-targeting medications have failed. It's addressing a different biological mechanism.

IV administration is specifically important because it delivers ketamine directly into the bloodstream at precisely controlled concentrations, bypassing first-pass hepatic metabolism and producing consistent, predictable plasma levels. This is why IV infusion produces the most robust and reliable response data in clinical trials — and why Magnolia uses IV infusion exclusively rather than intramuscular injection, nasal spray, or oral troches, all of which produce more variable absorption and less precise dosing.

What Conditions Respond to Ketamine Therapy

Treatment-resistant depression

The definition used in clinical research is typically failure to achieve adequate response after two or more antidepressant trials of adequate dose and duration. In clinical practice, many patients seeking ketamine therapy have failed considerably more than two. The evidence here is the strongest in the field: multiple randomized controlled trials and a substantial real-world outcomes literature consistently show 50-70% response rates in patients who have failed standard antidepressants. A 2019 meta-analysis in BMJ Open found that ketamine produced rapid and significant reduction in depressive symptoms versus placebo, with effects measurable within 24 hours of infusion.¹ For context, the response rate for a new antidepressant trial in a treatment-resistant patient is approximately 10-20%.

Anxiety and PTSD

The glutamate and NMDA receptor mechanisms that drive ketamine's antidepressant effects are also implicated in fear memory consolidation and extinction — the neurological processes disrupted in PTSD. Emerging evidence suggests ketamine may facilitate fear memory extinction and reduce hyperarousal symptoms in PTSD, with response rates comparable to those seen in depression. For refractory anxiety disorders where SSRIs and SNRIs have provided incomplete relief, ketamine offers a mechanism-based rationale for intervention that conventional medications don't. At Magnolia, anxiety and PTSD evaluations include a thorough psychiatric history and current medication review before any infusion series is initiated.

Chronic pain

NMDA receptor sensitization is a key mechanism in central sensitization — the process by which chronic pain conditions become self-perpetuating independent of the original injury or inflammation. Ketamine's NMDA antagonism directly interrupts this sensitization process, which is why it has established evidence in conditions including complex regional pain syndrome, fibromyalgia, neuropathic pain, and refractory migraine. The pain-modulating effects of ketamine can be distinct from — and additive with — its mood effects, making it particularly valuable for patients with both chronic pain and secondary depression, a combination I see frequently in inpatient medicine.

6 Ways Ketamine Clinics in DFW Are Failing Patients

Failure 1: No physician present during infusion

Ketamine is a dissociative anesthetic. At therapeutic doses for depression and pain, it produces altered perception, dissociation, and sometimes significant cardiovascular effects — transient blood pressure elevation and heart rate changes are common. This is not a procedure that should be administered without a physician in the room. Yet many DFW ketamine clinics run infusions supervised by nurses or NPs, with a physician available by phone. At Magnolia, Dr. Abdullah is on-site throughout every infusion. Every patient is evaluated personally by Dr. Abdullah before the infusion series begins. During infusions, a qualified NP administers and monitors under direct physician supervision — with Dr. Abdullah immediately available on-site, not by phone, if anything changes clinically. The distinction matters clinically — and it matters for patient safety.

Failure 2: No psychiatric screening before treatment

Ketamine is contraindicated or requires careful risk-benefit evaluation in patients with a history of psychosis, active mania, active substance use disorder (particularly dissociatives or stimulants), uncontrolled hypertension, and certain other conditions. A clinic that evaluates a patient with a brief intake form and approves them for infusion without a thorough psychiatric history, current medication review, and cardiovascular baseline has not done an adequate pre-treatment evaluation. At Magnolia, every patient completes a comprehensive intake that includes psychiatric history, current medication review, substance use history, and baseline vitals before any infusion is scheduled.

Failure 3: One-size-fits-all dosing

Standard IV ketamine dosing for depression is typically initiated at 0.5 mg/kg over 40 minutes — but this is a starting point, not a fixed protocol. Body weight, renal function, concurrent medications, prior ketamine exposure, and individual response all affect optimal dosing. Clinics that apply a single standard dose to every patient regardless of these variables are not practicing individualized medicine. At Magnolia, dosing is determined per patient at each session based on weight, clinical response, and tolerability — adjusted across the infusion series as needed.

Failure 4: No integration support or follow-up plan

The neuroplasticity window opened by ketamine — the period immediately following infusion during which the brain is in a heightened state of synaptic reorganization — is clinically meaningful. Patients who engage in integration support during this window, whether through therapy, structured reflection, or behavioral support, consistently show better long-term outcomes than patients who receive infusions without any psychological support component. Ketamine without integration is a treatment. Ketamine with integration is a program. At Magnolia, every patient receives a post-infusion follow-up plan and, where appropriate, referral to integration-supportive therapy.

Failure 5: Treating ketamine as a standalone cure rather than part of a broader protocol

Ketamine produces rapid, significant antidepressant and analgesic effects — but its duration is finite. Most patients experience peak effects in the days to weeks following an infusion series, with gradual attenuation thereafter. The clinical goal is to use that window to support broader therapeutic changes: psychotherapy engagement, lifestyle intervention, medication optimization, hormonal and metabolic evaluation where relevant. A clinic that provides infusions without any broader clinical context — no discussion of maintenance strategy, no evaluation of contributing factors, no coordination with other treating providers — is providing a procedure, not a program.

Failure 6: No physician actually managing your case

This is the same failure that runs through every service line in functional medicine — but it carries particular weight in ketamine therapy because of the monitoring requirements, contraindication complexity, and the vulnerability of the patient population. Treatment-resistant depression is serious. The patients seeking ketamine therapy have often already failed multiple treatments and are, in many cases, at meaningful psychiatric risk. They deserve a physician who has reviewed their full history, understands their current medication picture, and is on-site — not available by phone — during their infusion. At Magnolia, Dr. Abdullah evaluates every ketamine patient personally, is present throughout every infusion, and manages the follow-up plan directly.

The Magnolia Ketamine Protocol: Specifically What We Do

These are the attributable clinical standards Dr. Abdullah applies at Magnolia Functional Wellness for every ketamine patient.

Comprehensive pre-treatment evaluation. Psychiatric history, current medication review, substance use history, cardiovascular baseline, and contraindication screening — before any infusion is scheduled. Not an intake form. A clinical evaluation.

IV infusion exclusively. The delivery method with the strongest evidence base, most precise dosing, and most predictable plasma levels. Magnolia does not offer IM, nasal, or oral ketamine — because IV infusion is the standard that produces the outcomes the clinical literature is built on.

Individualized weight-based dosing, adjusted per session. Starting at 0.5 mg/kg with adjustment based on response, tolerability, and clinical picture. Every patient. Every session.

Dr. Abdullah present and monitoring throughout every infusion. Vitals monitored continuously. Physician in the room — not available by phone. This is non-negotiable at Magnolia.

Standard series of six infusions over two to three weeks. The evidence-based induction protocol for treatment-resistant depression. Spaced to allow cumulative neuroplasticity effects to develop. Maintenance infusions scheduled based on individual response and duration of effect.

Post-infusion integration support. Follow-up plan provided after every infusion. Referral to integration-supportive therapy where appropriate. Coordination with existing psychiatric providers when relevant.

Broader clinical context. At Magnolia, ketamine is evaluated in the context of the patient's full clinical picture — hormonal status, metabolic health, sleep, inflammation markers. Treatment-resistant depression does not exist in isolation. Contributing factors that are addressable should be addressed concurrently.

What to Expect: The Infusion Experience

An IV ketamine infusion at Magnolia takes approximately 40-60 minutes for the active infusion, plus preparation and recovery time. Patients are seated in a comfortable recliner in a calm, private setting. Vitals are monitored continuously. At therapeutic doses, most patients experience mild to moderate dissociation — a dreamlike or floating sensation, altered perception of time or space, sometimes visual changes. This is expected and manageable. Dr. Abdullah is present throughout.

Most patients are able to leave within 30-60 minutes of infusion completion once vitals have stabilized. Driving is not permitted on infusion days — patients need a driver. Most patients describe the infusion experience as manageable to pleasant; a minority find it anxiety-provoking, particularly on first infusion, which is why physician presence and patient preparation matter.

Antidepressant effects, when they occur, are typically noticed within 24 hours of the first or second infusion. Some patients notice a shift within hours. The standard induction series is six infusions — not because one or two won't produce a response, but because the cumulative series produces more durable effects than a single infusion.

Why Physician On-Site Supervision Isn't Standard in DFW Ketamine Clinics — and Why It Should Be

Texas law allows a physician to supervise a ketamine clinic through a prescriptive authority agreement that specifies how oversight will be handled. What the law does not require is that the physician be physically present in the building during infusions. In practice, this means a significant portion of DFW ketamine clinics operate with a physician who is reachable by phone — sometimes from another clinic, sometimes from home — while an NP or nurse administers and monitors the infusion on-site.

This is legal. It is not the same as physician on-site supervision.

Ketamine produces dissociation, altered perception, and reliable cardiovascular effects — transient blood pressure and heart rate changes are expected at therapeutic doses. In the rare event of an adverse reaction, laryngospasm, significant hypertensive response, or psychiatric emergency, the clinical response time when a physician is in the building is measured in seconds. The clinical response time when a physician is available by phone is measured in minutes — at best.

At Magnolia, Dr. Abdullah is physically on-site throughout every infusion. Every patient is evaluated personally by Dr. Abdullah before the infusion series begins — not by intake form, not by NP assessment alone. During infusions, a qualified NP administers and monitors under direct on-site physician supervision. If anything changes clinically, physician judgment is immediately available. That's not a marketing claim. It's a staffing model — and it's the standard Magnolia holds because the patient population seeking ketamine therapy deserves it.

Frequently Asked Questions

Am I a candidate for ketamine therapy?

Good candidates have typically failed two or more adequate antidepressant trials, or have anxiety, PTSD, or chronic pain that has not responded adequately to standard treatments. Ketamine requires careful evaluation in patients with a history of psychosis, active mania, active substance use disorder, or uncontrolled cardiovascular disease. The evaluation at Magnolia is designed to identify both candidacy and any contraindications before any infusion is scheduled. The best way to find out is a consultation — not a self-assessment checklist.

How is IV ketamine different from Spravato (esketamine nasal spray)?

Spravato is FDA-approved esketamine — the S-enantiomer of ketamine — administered as a nasal spray in a certified healthcare setting. IV racemic ketamine is off-label for depression but has a substantially larger and longer clinical evidence base than Spravato, including the randomized controlled trials and real-world outcomes data that established ketamine's role in treatment-resistant depression. IV administration also produces more precise and consistent plasma levels than nasal administration. At Magnolia, we use IV ketamine — not Spravato — for this reason.

How quickly does ketamine work?

This is the most clinically significant difference between ketamine and standard antidepressants. Most patients who respond notice improvement within 24-72 hours of their first or second infusion — some within hours. Standard antidepressants require 4-6 weeks to produce meaningful effect. For patients in acute distress or with active suicidal ideation, this speed of action is clinically important. It's also why ketamine has attracted significant research interest for acute suicidal crisis intervention.

How long do the effects last?

This varies significantly by patient and condition. After a standard six-infusion series, many patients experience sustained improvement for weeks to months. Some require maintenance infusions at intervals of 4-8 weeks to maintain effect. Others find that the series produces durable remission without maintenance. There is no reliable way to predict individual duration of response before treatment — which is why the follow-up plan and maintenance strategy are discussed at the outset rather than after the series ends.

Does ketamine interact with my current medications?

Some medications require evaluation before ketamine infusion — particularly benzodiazepines (which can blunt the response), lithium, and certain stimulants. MAOIs require specific washout. This is part of the pre-treatment evaluation at Magnolia. Do not adjust or stop any current medications before your consultation — medication management decisions are made as part of the clinical evaluation, not in advance of it.

Is ketamine covered by insurance?

IV ketamine infusion for depression and psychiatric indications is not currently covered by most major insurance plans. Spravato (esketamine) has some insurance coverage pathways as an FDA-approved medication, but IV ketamine remains largely out-of-pocket. This is one of the most common barriers to access for patients who would benefit from it — and one of the reasons that clinics which offer lower-quality protocols at lower price points find a ready market. The cost difference between a properly supervised IV infusion with physician presence and a nurse-monitored infusion without it is real, and it reflects a real difference in what's being delivered.

How do I know if a ketamine clinic actually has a physician present during infusion?

Ask directly: "Will the physician be in the room during my infusion, or available by phone?" The answer to that question tells you what you need to know. In Texas, a physician can satisfy the legal requirements of a ketamine clinic through a supervisory structure that never puts them in the room. At Magnolia, Dr. Abdullah is on-site throughout every infusion. Every patient is evaluated personally before treatment. During infusion, physician oversight is immediate and on-site — not a phone call away. That's a clinical standard, not a legal minimum.

If you've exhausted standard antidepressant options, or if you're living with anxiety, PTSD, or chronic pain that conventional treatment hasn't adequately addressed, ketamine therapy may be the most significant intervention you haven't yet tried. Learn more about IV ketamine therapy at Magnolia Functional Wellness — or call 817-329-0102. Southlake clinic, with telehealth consultations available statewide.